(S (ADVP (NNP Herein)) (NP (PRP we)) (VP (VBP propose) (NP (NP (DT a) (ADJP (JJ deep) (JJ learning-based)) (NN approach)) (PP (IN for) (NP (NP (DT the) (NN prediction)) (PP (IN of) (NP (NN lung) (NN lesion) (NN response))))) (PP (VBN based) (PP (IN on) (NP (NP (JJ radiomic) (NNS features)) (VP (VBN extracted) (PP (IN from) (NP (NP (JJ clinical) (NNP CT) (NNS scans)) (PP (IN of) (NP (NP (NNS patients)) (PP (IN in) (NP (JJ non-small) (NN cell) (NN lung) (NN cancer) (NNS trials))))))))))))) (. .))
(S (NP (DT The) (NN approach)) (VP (VBZ starts) (PP (IN with) (NP (NP (DT the) (NN classification)) (PP (IN of) (NP (NN lung) (NNS lesions))) (PP (IN from) (NP (NP (DT the) (NN set)) (PP (IN of) (NP (NP (ADJP (JJ primary) (CC and) (JJ metastatic)) (NNS lesions)) (PP (IN at) (NP (JJ various) (JJ anatomic) (NNS locations)))))))))) (. .))
(S (S (VP (VBG Focusing) (PP (IN on) (NP (DT the) (NN lung) (NNS lesions))))) (, ,) (NP (PRP we)) (VP (VBP perform) (NP (JJ automatic) (NN segmentation)) (S (VP (TO to) (VP (VB extract) (NP (PRP$ their) (CD 3D) (NNS volumes)))))) (. .))
(S (NP (JJ Radiomic) (NNS features)) (VP (VBP are) (ADVP (RB then)) (VP (VBN extracted) (PP (IN from) (NP (DT the) (NN lesion))) (PP (IN on) (NP (NP (DT the) (JJ pre-treatment) (JJ scan)) (CC and) (NP (DT the) (JJ first) (JJ follow-up) (NN scan)))) (S (VP (TO to) (VP (VB predict) (SBAR (WHNP (WDT which) (NNS lesions)) (S (VP (MD will) (VP (VP (VB shrink) (NP (QP (IN at) (JJS least) (CD 30)) (NN %)) (PP (IN in) (NP (NN diameter))) (PP (IN during) (NP (NN treatment))) (PRN (-LRB- -LRB-) (NP (CC either) (NP (NNP Pembrolizumab)) (CC or) (NP (NP (NNS combinations)) (PP (IN of) (NP (NN chemotherapy) (CC and) (NNP Pembrolizumab))))) (-RRB- -RRB-))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBZ is) (VP (VBN defined) (PP (IN as) (NP (DT a) (JJ partial) (NN response))) (PP (IN by) (NP (DT the) (NNP Response) (NNP Evaluation) (NNP Criteria) (PP (IN In) (NP (NNP Solid) (NNP Tumors))) (PRN (PRN (-LRB- -LRB-) (NP (NNP RECIST)) (-RRB- -RRB-)) (NNS guidelines))))))))))))))))) (. .))
(S (S (NP (NP (DT A) (JJ 5-fold) (NN cross) (NN validation)) (PP (IN on) (NP (DT the) (NN training) (NN set)))) (VP (VBD led) (PP (TO to) (NP (NP (DT an) (NNP AUC)) (PP (IN of) (NP (CD 0.84) (JJ +/-) (CD 0.03))))))) (, ,) (CC and) (S (NP (NP (DT the) (NN prediction)) (PP (IN on) (NP (DT the) (NN testing) (NN dataset)))) (VP (VBD reached) (NP (NP (NNP AUC)) (PP (IN of) (NP (CD 0.73) (JJ +/-) (CD 0.02)))) (PP (IN for) (NP (NP (DT the) (NN outcome)) (PP (IN of) (NP (ADJP (CD 30) (NN %)) (NN diameter) (NN shrinkage))))))) (. .))
